尼莫地平注射液联合参附注射液治疗创伤性蛛网膜下腔出血的临床研究

发布时间：2018-05-13 07:00

  本文选题：尼莫地平注射液 + 参附注射液　； 参考：《中国临床药理学杂志》2017年19期

【摘要】：目的观察创伤性蛛网膜下腔出血用于尼莫地平注射液联合参附注射液的临床疗效。方法将84例创伤性蛛网膜下腔出血患者随机分为对照组与试验组,每组42例。对照组给予尼莫地平注射液20 mg,qd,静脉滴注;试验组在对照组的基础上给予参附注射液30 mL+5%葡萄糖注射液250 m L,bid,静脉滴注。2组均连续用药14 d。比较2组患者的临床疗效、炎症因子水平、凝血功能及药物不良反应发生情况。结果治疗后,试验组预后良好率为69.05%(29/42例),对照组为47.62%(20/42例),差异有统计学意义(P0.05)。试验组白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、凝血酶原时间、部分凝血活酶时间分别为(0.85±0.11)μg·L~(-1),(0.57±0.07)μg·L~(-1),(12.40±1.66)s,(33.75±3.88)s,对照组分别为(1.06±0.15)μg·L~(-1),(1.06±0.13)μg·L~(-1),(14.69±1.63)s,(36.69±4.44)s,差异均有统计学意义(P0.05)。对照组出现脑梗死4例,脑积水2例,脑出血6例,脑血管痉挛6例,药物不良反应率为42.86%(18/42例);试验组出现脑梗死和脑积水各1例,脑出血和脑血管痉挛各2例,药物不良反应率为14.28%(6/42例),差异有统计学意义(P0.05)。结论尼莫地平注射液联合参附注射液用于创伤性蛛网膜下腔出血的临床效果较好,能够利于患者预后,改善炎症反应及凝血功能。
[Abstract]:Objective to observe the clinical effect of Nimodipine injection combined with Shenfu injection on traumatic subarachnoid hemorrhage. Methods 84 patients with traumatic subarachnoid hemorrhage were randomly divided into control group and experimental group with 42 cases in each group. The control group was given nimodipine injection 20 mg / g QD, and the experimental group was given Shenfu injection 30 mL 5% glucose injection 250 mL / L bid for 14 days. The clinical efficacy, inflammatory factor level, coagulation function and adverse drug reaction were compared between the two groups. Results after treatment, the good prognosis rate of the trial group was 69.05 / 29 / 42 cases, while that of the control group was 47.622% 20 / 42 cases. The difference was statistically significant (P 0.05). 璇曢獙缁勭櫧缁嗚優浠嬬礌-6(IL-6),鑲跨槫鍧忔�诲洜瀛�-伪(TNF-伪),鍑濊��閰跺師鏃堕棿,閮ㄥ垎鍑濊��娲婚叾鏃堕棿鍒嗗埆涓，

本文编号：1882150